泌尿系恶性肿瘤中长非编码RNA的预后价值：系统综述和荟萃分析

Q3 Medicine

Open Biomarkers Journal Pub Date : 2021-12-20 DOI:10.2174/1875318302111010115

Z. Bagheri, Mohammad-Hassan Arjmand

{"title":"泌尿系恶性肿瘤中长非编码RNA的预后价值：系统综述和荟萃分析","authors":"Z. Bagheri, Mohammad-Hassan Arjmand","doi":"10.2174/1875318302111010115","DOIUrl":null,"url":null,"abstract":"\n \n Many studies have explored the potential roles of long non-coding RNAs (lncRNAs) in urological cancer (UC) progression. The clinical outcome and prognosis of UCs remain weak. Therefore, finding clinical prognostic markers is needed to improve therapeutic potential. The aim of this study was to consider the possible association between the lncRNAs expression with the survival time and clinical outcomes in patients with UC.\n \n \n \n A literature search was performed in several related databases to find eligible English papers published before 9 February 2021. Hazard ratios (HRs) with 95% CI were calculated to investigate the association between lncRNAs expression and overall survival in patients with UC.\n \n \n \n A total of 46 studies, including 39 lncRNAs were identified. Results indicated that lncRNAs expression was significantly correlated with poor overall survival (OS) outcome in patients with UCs (HR: 1.923, 95% CI: 1.448-2.554, P<0.001). Also, we divided included studies into up-regulated and down-regulated subgroups according to lncRNAs expression. The results indicated a significant association with poor OS outcomes in both up-regulated (HR=2.546, 95% CI: 1.896-3.41, P<0.001) and down-regulated (HR=0.33, 95% CI: 0.22-0.49, P<0.001). Moreover, expression of lncRNAs was significantly associated with lymph node metastasis (LNM) (OR=0.25, 95% CI: 0.13-0.47, P<0.001)\n \n \n \n Abnormal expression of various lncRNAs is a potential novel marker for predicting the clinical outcomes of urological tumors.\n","PeriodicalId":39398,"journal":{"name":"Open Biomarkers Journal","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Value of Long Non-coding RNAs in Urological Malignancies: A Systematic Review, and Meta-Analysis\",\"authors\":\"Z. Bagheri, Mohammad-Hassan Arjmand\",\"doi\":\"10.2174/1875318302111010115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n Many studies have explored the potential roles of long non-coding RNAs (lncRNAs) in urological cancer (UC) progression. The clinical outcome and prognosis of UCs remain weak. Therefore, finding clinical prognostic markers is needed to improve therapeutic potential. The aim of this study was to consider the possible association between the lncRNAs expression with the survival time and clinical outcomes in patients with UC.\\n \\n \\n \\n A literature search was performed in several related databases to find eligible English papers published before 9 February 2021. Hazard ratios (HRs) with 95% CI were calculated to investigate the association between lncRNAs expression and overall survival in patients with UC.\\n \\n \\n \\n A total of 46 studies, including 39 lncRNAs were identified. Results indicated that lncRNAs expression was significantly correlated with poor overall survival (OS) outcome in patients with UCs (HR: 1.923, 95% CI: 1.448-2.554, P<0.001). Also, we divided included studies into up-regulated and down-regulated subgroups according to lncRNAs expression. The results indicated a significant association with poor OS outcomes in both up-regulated (HR=2.546, 95% CI: 1.896-3.41, P<0.001) and down-regulated (HR=0.33, 95% CI: 0.22-0.49, P<0.001). Moreover, expression of lncRNAs was significantly associated with lymph node metastasis (LNM) (OR=0.25, 95% CI: 0.13-0.47, P<0.001)\\n \\n \\n \\n Abnormal expression of various lncRNAs is a potential novel marker for predicting the clinical outcomes of urological tumors.\\n\",\"PeriodicalId\":39398,\"journal\":{\"name\":\"Open Biomarkers Journal\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-12-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Biomarkers Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1875318302111010115\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Biomarkers Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875318302111010115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

许多研究已经探索了长非编码RNA（lncRNA）在泌尿外科癌症（UC）进展中的潜在作用。UC的临床结果和预后仍然很差。因此，需要找到临床预后标志物来提高治疗潜力。本研究的目的是考虑lncRNA的表达与UC患者的生存时间和临床结果之间的可能联系。在几个相关数据库中进行了文献检索，以查找2021年2月9日之前发表的符合条件的英文论文。计算95%CI的危险比（HR），以研究lncRNA表达与UC患者总生存率之间的关系。共鉴定了46项研究，其中包括39个lncRNA。结果表明，lncRNAs的表达与UC患者的不良总生存率（OS）结果显著相关（HR:1.923，95%CI:1.448-2.554，P<0.001）。此外，我们根据lncRNA的表达将纳入研究分为上调和下调亚组。结果表明，无论是上调（HR=2.546，95%CI:1.896-3.41，P<0.001）还是下调（HR=0.33，95%CI:0.22-0.49，P<0.001，lncRNAs的表达与淋巴结转移（LNM）显著相关（OR=0.25，95%CI:0.13-0.47，P<0.001）各种lncRNA的异常表达是预测泌尿系统肿瘤临床结果的潜在新标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prognostic Value of Long Non-coding RNAs in Urological Malignancies: A Systematic Review, and Meta-Analysis

Many studies have explored the potential roles of long non-coding RNAs (lncRNAs) in urological cancer (UC) progression. The clinical outcome and prognosis of UCs remain weak. Therefore, finding clinical prognostic markers is needed to improve therapeutic potential. The aim of this study was to consider the possible association between the lncRNAs expression with the survival time and clinical outcomes in patients with UC. A literature search was performed in several related databases to find eligible English papers published before 9 February 2021. Hazard ratios (HRs) with 95% CI were calculated to investigate the association between lncRNAs expression and overall survival in patients with UC. A total of 46 studies, including 39 lncRNAs were identified. Results indicated that lncRNAs expression was significantly correlated with poor overall survival (OS) outcome in patients with UCs (HR: 1.923, 95% CI: 1.448-2.554, P<0.001). Also, we divided included studies into up-regulated and down-regulated subgroups according to lncRNAs expression. The results indicated a significant association with poor OS outcomes in both up-regulated (HR=2.546, 95% CI: 1.896-3.41, P<0.001) and down-regulated (HR=0.33, 95% CI: 0.22-0.49, P<0.001). Moreover, expression of lncRNAs was significantly associated with lymph node metastasis (LNM) (OR=0.25, 95% CI: 0.13-0.47, P<0.001) Abnormal expression of various lncRNAs is a potential novel marker for predicting the clinical outcomes of urological tumors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Open Biomarkers Journal Medicine-Medicine (miscellaneous)

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： The Open Biomarkers Journal is an Open Access online journal, which publishes original full-length, short research articles and reviews on biomarkers in clinical, medical and pharmaceutical research. The coverage includes biomarkers of disease, new biomarkers, exposure to drugs, genetic effects, and applications of biomarkers. The Open Biomarkers Journal, a peer reviewed journal, aims to provide the most complete and reliable source of information on current developments in the field. The emphasis will be on publishing quality articles rapidly and freely available to researchers worldwide.